Novo Nordisk (NVO) Stock May Trade Below Fair Value Despite Obesity Market Lawsuit

Novo Nordisk stock combines a weak three year share price record with valuation checks that still lean supportive, which raises questions about how much pessimism is already reflected in today’s price.

• Over the past three years the share price has declined 45.7%, which suggests investors have meaningfully reset their expectations for the business.
• Expectations around Novo Nordisk’s ability to grow and defend its position in the obesity treatment market can support the investment case. At the same time, competitive pressure highlighted by the recent Eli Lilly dispute over obesity drug advertising may weigh on how much investors are willing to pay.
• The stock screens as undervalued in 5 of 6 valuation checks, so the broader set of metrics leans toward the shares being priced cautiously rather than optimistically.

The issue now is whether that cautious pricing already reflects the competitive and legal risks around Novo Nordisk, or if the recent share price weakness still overstates them.

Find out why Novo Nordisk's -9.1% return over the last year is lagging behind its peers.

Is Novo Nordisk a Bargain on Earnings?

P/E is usually a good starting point for a profitable, mature business like Novo Nordisk, where earnings are a key driver of value. Novo Nordisk currently trades on a P/E of about 11.7x, which is below the wider pharmaceuticals industry average of 16.8x and far below the peer group average near 51.4x. That puts the stock on a lower earnings multiple than many investors might expect for a major player in obesity and diabetes treatments.

The fair P/E multiple implied by the model is 25.8x, which is more than double the current 11.7x. This gap suggests that, based on factors such as profitability profile, market position and sector risks, the shares trade at a meaningful discount to what the model would expect. Despite the legal dispute with Eli Lilly around obesity drug advertising, the current earnings multiple still prices Novo Nordisk below both the tailored fair multiple and key peers.

On the P/E multiple, Novo Nordisk stock appears undervalued compared with both the modelled fair ratio and the broader pharmaceuticals sector.

See what the numbers say about this price — find out in our valuation breakdown.

The Novo Nordisk Narrative: What Would Justify Today's Price?

Simply Wall St Narratives build on this valuation puzzle around Novo Nordisk's P/E and examine what would need to be true about Novo Nordisk's future growth, margins and earnings for the stock to be worth substantially more or less than it is today, using a set of transparent scenarios that live on Simply Wall St's Community page. Rather than rely on a single multiple or model output, each one lays out its assumptions so you can compare them with the company’s actual results over time.

One of the top community narratives on Novo Nordisk: 49% undervalued

"Current sentiment has swung deeply negative, but expectations are now low, and the market appears to assign little to no value to Novo’s development-stage pipeline beyond Wegovy…"

Read one of the top narratives on Novo Nordisk

Do you think there's more to the story for Novo Nordisk? Head over to our Community to see what others are saying!

The Bottom Line

Novo Nordisk screens as undervalued on earnings multiples, which suggests the market is pricing in a fair amount of caution already. The key question is whether that discount proves to be compensation for real competitive and legal risks or a gap that closes if sentiment improves. For now, the debate turns on one main assumption: whether Novo Nordisk can protect its obesity and diabetes franchise against rivals while maintaining the kind of profitability that might justify a higher P/E over time.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com